860476-76-2

Basic information

• Product Name: C₆₀H₇₇N₅O₁₆
• Synonyms: C₆₀H₇₇N₅O₁₆
• CAS NO: 860476-76-2
• Molecular Weight: 1124.3
• Mol File: 860476-76-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₆₀H₇₇N₅O₁₆(CAS DataBase Reference)
• NIST Chemistry Reference: C₆₀H₇₇N₅O₁₆(860476-76-2)
• EPA Substance Registry System: C₆₀H₇₇N₅O₁₆(860476-76-2)

Safety Data

• Hazardous Substances Data: 860476-76-2(Hazardous Substances Data)

Upstream product

• 892860-26-3 (3-quinoxalin-6-yl-propyl)-carbamic acid tert-butyl ester 
• 892860-23-0 (3-quinoxalin-6-yl-prop-2-ynyl)-carbamic acid tert-butyl ester 
• 50998-17-9 6-bromoquinoxaline 
• 860476-71-7 2-{10-[4-(benzyloxycarbonyl-methyl-amino)-3-benzyloxycarbonyloxy-6-methyl-tetrahydro-pyran-2-yloxy]-2-ethyl-3,4-dihydroxy-9-methoxy-3,5,7,9,11,13-hexamethyl-12,14-dioxo-oxacyclotetradec-6-ylideneaminooxy}-propionic acid allyl ester 
• 860476-73-9 C₅₂H₇₀N₂O₁₇ 
• 860476-70-6 carbonic acid benzyl ester 4-(benzyloxycarbonyl-methyl-amino)-2-(14-ethyl-12,13-dihydroxy-10-hydroxyimino-7-methoxy-3,5,7,9,11,13-hexamethyl-2,4-dioxo-oxacyclotetradec-6-yloxy)-6-methyl-tetrahydro-pyran-3-yl ester 
• 860476-77-3 3-quinoxalin-6-yl-propylamine 
• 860476-74-0 C₄₉H₆₆N₂O₁₇ 

Relevant articles and documents

A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether: Synthesis and structure-activity relationships (2)

A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether and its analogues were prepared, and their antibacterial activities and pharmacokinetic properties were evaluated. We found that the introduction of an (R)-alkyl group between the amide and iminoether groups could improve the pharmacokinetic properties while maintaining the activity against erythromycin-resistant Streptococcus pneumoniae. Among the ketolides prepared with the (R)-alkyl group, compound 5p with an N-(3-quinoxalin-6-yl-propyl)-propionamide moiety was found to have in vivo efficacy comparable to CAM with potent in vitro antibacterial activities against the key respiratory pathogens including Haemophilus influenzae and erythromycin-resistant S. pneumoniae.